论文部分内容阅读
慢性髓性白血病(CML)属于多能造血干细胞恶性骨髓增生性疾病,费城(Ph)染色体是CML的细胞遗传学标志,90%以上CML患者骨髓细胞中发现有Ph染色体。经过20年的研究,CML患者的生存预后得到显著改善,特别是伊马替尼(imatinib,商品名格列卫)成功应用于临床治疗CML。伊马替尼是酪氨酸激酶抑制剂,目前是CML慢性期(CML-CP)最有效的靶向治疗药物。2009年ASH年会上报告了伊马替尼用于CML一线治疗的IRIS研究(国际干扰素和STI571随机研究)随访8年的最新结果,本文对该项研究结果进行综述。
Chronic myelogenous leukemia (CML) belongs to the multipotent hematopoietic stem cell malignant myeloproliferative disease. The Ph chromosome is a cytogenetical marker of CML. Ph chromosome is found in bone marrow cells of more than 90% of CML patients. After 20 years of research, the survival prognosis of CML patients has been significantly improved, especially imatinib (Gleevec) has been successfully used in the clinical treatment of CML. Imatinib is a tyrosine kinase inhibitor and is currently the most effective targeted therapy for chronic phase CML (CML-CP). The latest results of the 8-year follow-up of the IRIS study of Imatinib for the first-line treatment of CML (International Interferon and STI 571 Randomized Study) were reported at the 2009 ASH Annual Meeting, and the results of this study are reviewed.